Review



splicing rbpms antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Proteintech splicing rbpms antibody
    Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of <t>RBPMS</t> staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; <t>RBPMS:</t> <t>RNA</t> binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.
    Splicing Rbpms Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 80 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/splicing rbpms antibody/product/Proteintech
    Average 95 stars, based on 80 article reviews
    splicing rbpms antibody - by Bioz Stars, 2026-02
    95/100 stars

    Images

    1) Product Images from "Synapses and dendritic spines are eliminated in the primary visual cortex of mice subjected to chronic intraocular pressure elevation"

    Article Title: Synapses and dendritic spines are eliminated in the primary visual cortex of mice subjected to chronic intraocular pressure elevation

    Journal: Neural Regeneration Research

    doi: 10.4103/NRR.NRR-D-24-00394

    Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of RBPMS staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; RBPMS: RNA binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.
    Figure Legend Snippet: Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of RBPMS staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; RBPMS: RNA binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.

    Techniques Used: Injection, Control, Staining, RNA Binding Assay



    Similar Products

    splicing rbpms antibody  (Proteintech)
    95
    Proteintech splicing rbpms antibody
    Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of <t>RBPMS</t> staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; <t>RBPMS:</t> <t>RNA</t> binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.
    Splicing Rbpms Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/splicing rbpms antibody/product/Proteintech
    Average 95 stars, based on 1 article reviews
    splicing rbpms antibody - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    rabbit anti rbpms  (Proteintech)
    95
    Proteintech rabbit anti rbpms
    Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of <t>RBPMS</t> staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; <t>RBPMS:</t> <t>RNA</t> binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.
    Rabbit Anti Rbpms, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti rbpms/product/Proteintech
    Average 95 stars, based on 1 article reviews
    rabbit anti rbpms - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    15187 1 ap  (Proteintech)
    95
    Proteintech 15187 1 ap
    Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of <t>RBPMS</t> staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; <t>RBPMS:</t> <t>RNA</t> binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.
    15187 1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/15187 1 ap/product/Proteintech
    Average 95 stars, based on 1 article reviews
    15187 1 ap - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    anti rbpms  (Proteintech)
    95
    Proteintech anti rbpms
    Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of <t>RBPMS</t> staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; <t>RBPMS:</t> <t>RNA</t> binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.
    Anti Rbpms, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti rbpms/product/Proteintech
    Average 95 stars, based on 1 article reviews
    anti rbpms - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    mrna processing factor rbpms  (Proteintech)
    95
    Proteintech mrna processing factor rbpms
    Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of <t>RBPMS</t> staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; <t>RBPMS:</t> <t>RNA</t> binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.
    Mrna Processing Factor Rbpms, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mrna processing factor rbpms/product/Proteintech
    Average 95 stars, based on 1 article reviews
    mrna processing factor rbpms - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    rbpms polyclonal antibody  (Proteintech)
    95
    Proteintech rbpms polyclonal antibody
    Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of <t>RBPMS</t> staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; <t>RBPMS:</t> <t>RNA</t> binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.
    Rbpms Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rbpms polyclonal antibody/product/Proteintech
    Average 95 stars, based on 1 article reviews
    rbpms polyclonal antibody - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    pan rbpms  (Proteintech)
    95
    Proteintech pan rbpms
    (A) <t>RBPMS</t> and RBPMS2 (green) are localized to the nuclei (DAPI, grey) of cardiomyocytes (CMs, marked <t>by</t> <t>Nkx2–5,</t> red). (B) RBPMS and RBPMS2 (green) are localized to the nuclei of vascular smooth muscle cells (SMCs, marked by αSMA/α smooth muscle actin, red) in coronary vessels and aorta. (C) RBPMS and RBPMS2 (green) are localized to the nuclei of endothelial cells (ECs, marked by endomucin/EMCN, blue). (D) RBPMS and RBPMS2 (green) are localized to the nuclei of fibroblasts (FBs, marked by PDGFRα, red). Yellow arrows: CM nuclei; Orange arrows: SMC nuclei; Blue arrows: EC nuclei; Magenta arrows: FB nuclei. Rbpms global KO samples ( Rbpms gKO ) were used as negative controls. Scale bar: 20 μm.
    Pan Rbpms, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pan rbpms/product/Proteintech
    Average 95 stars, based on 1 article reviews
    pan rbpms - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of RBPMS staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; RBPMS: RNA binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.

    Journal: Neural Regeneration Research

    Article Title: Synapses and dendritic spines are eliminated in the primary visual cortex of mice subjected to chronic intraocular pressure elevation

    doi: 10.4103/NRR.NRR-D-24-00394

    Figure Lengend Snippet: Induction of OHT via magnetic microbead injection, and RGC loss. (A) Defined regions (450 µm × 320 µm) in the central, middle, and peripheral regions of the retina are indicated by boxes. Scale bar: 500 µm. (B) The IOP curve following anterior chamber injection of magnetic microbeads ( n = 10/group, mean ± SD, *** P < 0.001, vs . control; two-way analysis of variance followed by Sidak’s multiple comparisons test). (C) Representative images of RBPMS staining (Alexa Flour 488, green) in the central, middle, and peripheral regions of the retina in the NC group and on the OHT side at 4, 6, and 8 weeks. After 4, 6, and 8 weeks of OHT, the RGCs in the central, middle, and peripheral regions of the retina on the OHT side were significantly reduced compared with the NC group. Scale bars: 50 µm. (D–F) Quantification of RBPMS-positive RGCs at 4, 6, and 8 weeks post‐OHT in the central (D), middle (E), and peripheral (F) regions of the retina in the NC group and on the OHT side ( n = 6/group, mean ± SD, *** P < 0.001, two-way analysis of variance followed by Sidak’s multiple comparisons test). IOP: Intraocular pressure; NC: no-treatment control; ns: not significant; OHT: ocular hypertension; RBPMS: RNA binding protein with multiple splicing; RGC: retinal ganglion cell; w: week.

    Article Snippet: The retinas were permeabilized using 2% Triton X-100, followed by a 2-hour blocking step with 5% goat serum (Boster, Wuhan, China), and subsequently incubated overnight at 4°C with an anti-RNA binding protein with multiple splicing (RBPMS) antibody (rabbit, 1:100, ProteinTech, Rosemont, IL, USA, Cat# 15187-1-AP, RRID: AB_2238431).

    Techniques: Injection, Control, Staining, RNA Binding Assay

    (A) RBPMS and RBPMS2 (green) are localized to the nuclei (DAPI, grey) of cardiomyocytes (CMs, marked by Nkx2–5, red). (B) RBPMS and RBPMS2 (green) are localized to the nuclei of vascular smooth muscle cells (SMCs, marked by αSMA/α smooth muscle actin, red) in coronary vessels and aorta. (C) RBPMS and RBPMS2 (green) are localized to the nuclei of endothelial cells (ECs, marked by endomucin/EMCN, blue). (D) RBPMS and RBPMS2 (green) are localized to the nuclei of fibroblasts (FBs, marked by PDGFRα, red). Yellow arrows: CM nuclei; Orange arrows: SMC nuclei; Blue arrows: EC nuclei; Magenta arrows: FB nuclei. Rbpms global KO samples ( Rbpms gKO ) were used as negative controls. Scale bar: 20 μm.

    Journal: Circulation research

    Article Title: RBPMS and RBPMS2 Cooperate to Safeguard Cardiac Splicing

    doi: 10.1161/CIRCRESAHA.125.326948

    Figure Lengend Snippet: (A) RBPMS and RBPMS2 (green) are localized to the nuclei (DAPI, grey) of cardiomyocytes (CMs, marked by Nkx2–5, red). (B) RBPMS and RBPMS2 (green) are localized to the nuclei of vascular smooth muscle cells (SMCs, marked by αSMA/α smooth muscle actin, red) in coronary vessels and aorta. (C) RBPMS and RBPMS2 (green) are localized to the nuclei of endothelial cells (ECs, marked by endomucin/EMCN, blue). (D) RBPMS and RBPMS2 (green) are localized to the nuclei of fibroblasts (FBs, marked by PDGFRα, red). Yellow arrows: CM nuclei; Orange arrows: SMC nuclei; Blue arrows: EC nuclei; Magenta arrows: FB nuclei. Rbpms global KO samples ( Rbpms gKO ) were used as negative controls. Scale bar: 20 μm.

    Article Snippet: Sources for antibodies used in immunofluorescence in this study: pan-RBPMS, 15187–1-AP (Proteintech); Nkx2–5, sc-8697 (Santa Cruz Biotechnology); EMCN, 14–5851-82 (Invitrogen); αSMA, ab7817 (Abcam); PDGFRα, AF1062 (R&D System); α-actinin-2, ab68167 (Abcam); Myom1, B4 (DSHB).

    Techniques: Expressing

    (A) Kaplan-Meier survival curves of control (n=7) and Rbpms cmKO (n=5) mice. (B) Representative hematoxylin and eosin (H&E)-stained sections from control and Rbpms cmKO mice at embryonic day 17.5 (E17.5) and postnatal day 30 (P30). Orange rulers indicate left ventricle (LV) trabeculae thickness while red rulers indicate LV compact layer thickness; Scale bar: 1 mm (whole heart view); 0.5 mm (magnified view). (C) Quantification of the thickness of the LV compact layer (LV-Com), LV trabeculae (LV-Tra), and interventricular septum (IVS) on H&E sections from control (n=5) and Rbpms cmKO (n=4) mice at E17.5. p-values were determined by Mann-Whitney test. (D) Echocardiography analysis of control (n=7) and Rbpms cmKO (n=5) mice at P30. p-values were determined by Mann-Whitney test. FS: fraction shortening; LV-IDd/s: LV internal dimension, diastolic/systolic; LV-PWd: LV posterior wall thickness, diastolic; IVSd: interventricular septum thickness, diastolic. (E) Left panel: representative immunostaining images of LV-com of E17.5 control and Rbpms cmKO mice using antibodies against Nkx2–5 (red), EdU signal (green), and DAPI (blue). Arrows indicate EdU-positive cardiomyocytes (CMs). Scale bar: 50 μm. Right panel: quantification (%) of EdU-positive CMs in E17.5 control (n=4) vs. Rbpms cmKO (n=4) heart areas as indicated. p-values were determined by Mann-Whitney test.

    Journal: Circulation research

    Article Title: RBPMS and RBPMS2 Cooperate to Safeguard Cardiac Splicing

    doi: 10.1161/CIRCRESAHA.125.326948

    Figure Lengend Snippet: (A) Kaplan-Meier survival curves of control (n=7) and Rbpms cmKO (n=5) mice. (B) Representative hematoxylin and eosin (H&E)-stained sections from control and Rbpms cmKO mice at embryonic day 17.5 (E17.5) and postnatal day 30 (P30). Orange rulers indicate left ventricle (LV) trabeculae thickness while red rulers indicate LV compact layer thickness; Scale bar: 1 mm (whole heart view); 0.5 mm (magnified view). (C) Quantification of the thickness of the LV compact layer (LV-Com), LV trabeculae (LV-Tra), and interventricular septum (IVS) on H&E sections from control (n=5) and Rbpms cmKO (n=4) mice at E17.5. p-values were determined by Mann-Whitney test. (D) Echocardiography analysis of control (n=7) and Rbpms cmKO (n=5) mice at P30. p-values were determined by Mann-Whitney test. FS: fraction shortening; LV-IDd/s: LV internal dimension, diastolic/systolic; LV-PWd: LV posterior wall thickness, diastolic; IVSd: interventricular septum thickness, diastolic. (E) Left panel: representative immunostaining images of LV-com of E17.5 control and Rbpms cmKO mice using antibodies against Nkx2–5 (red), EdU signal (green), and DAPI (blue). Arrows indicate EdU-positive cardiomyocytes (CMs). Scale bar: 50 μm. Right panel: quantification (%) of EdU-positive CMs in E17.5 control (n=4) vs. Rbpms cmKO (n=4) heart areas as indicated. p-values were determined by Mann-Whitney test.

    Article Snippet: Sources for antibodies used in immunofluorescence in this study: pan-RBPMS, 15187–1-AP (Proteintech); Nkx2–5, sc-8697 (Santa Cruz Biotechnology); EMCN, 14–5851-82 (Invitrogen); αSMA, ab7817 (Abcam); PDGFRα, AF1062 (R&D System); α-actinin-2, ab68167 (Abcam); Myom1, B4 (DSHB).

    Techniques: Control, Staining, MANN-WHITNEY, Immunostaining